METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN THE PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIAS WITH ANTI-TUMOR PREPARATIONS DAUNORUBICIN AND CYTOSINE-ARABINOSIDE Russian patent published in 2019 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention refers to oncohematology. Method for predicting the clinical effectiveness of the AML patient is characterized by the fact that the patient is taken a blood or bone marrow sample, recovering the tumor cells, culturing them with duanorubicin and cytosine arabinoside separately, adding a WST-1 solution, determining the relative density of living cells in the wells of the plate and IC50 for each cytostatic preparation, with the IC50 value for daunorubicin falling within range of 0.014–0.25 mcM/l; from more than 0.25 to 0.5, including 0.5 mcM/l; more than 0.5 mcM/l, and the IC50 value for cytarabine falling within range of 0.3–1.5 mcM/l, from more than 1.5 to 8, including 8 mcM/l; more than 8 mcM/l, respectively, high, medium or low sensitivity of tumor cells in vitro to daunorubicin and cytarabine, respectively; and data on sensitivity of tumor cells of patient to daunorubicin and cytarabine shows clinical effectiveness of AML patient with said preparations.

EFFECT: what is presented is a method for predicting the clinical effectiveness of the AML patient.

10 cl, 1 dwg, 3 tbl, 1 ex